INOVIO to Showcase Innovations at Major Upcoming Investor Conferences

INOVIO's Upcoming Investor Conferences

INOVIO Pharmaceuticals, Inc. (NASDAQ: INO), a leading player in biotechnology, has announced its participation in several important investor conferences this month, aiming to present its innovative work in developing DNA medicines. Known for addressing serious health challenges, including HPV-related diseases, cancer, and infectious diseases, INOVIO is on a mission to transform the landscape of disease treatment through its advanced technology.

Conference Details

The biotech firm will be part of the Cantor Global Healthcare Conference in New York on September 9th. During this event, INOVIO's management will engage in a fireside chat at 3:20 PM ET, allowing investors and stakeholders to gain insights into the company's strategic direction and breakthroughs. A webcast of this session will be available, providing broader access to those interested.

In addition, INOVIO will also feature at the H.C. Wainwright 28th Annual Global Investment Conference, with a presentation set to launch on September 11th at 7:00 AM ET. This virtual format offers another opportunity for investors to connect with INOVIO’s progress and vision for the future. The link to the conference presentation will be made available in advance, ensuring that interested parties can attend from anywhere.

Both conferences will also include one-on-one meetings between INOVIO’s management team and investors, offering an intimate setting for discussions that delve deeper into INOVIO's innovations and financial prospects. Replays of the presentations can be accessed for 90 days, allowing for continued engagement with audiences well beyond the live events.

About INOVIO Pharmaceuticals

Founded with a vision to combat some of the most pressing health issues of our time, INOVIO specializes in the development of DNA medicines. These innovative therapies are not merely treatments; they empower the body to produce its own disease-fighting mechanisms. The company's groundbreaking approach is positioned to make a significant impact in fields that include oncology and infectious diseases, illustrating remarkable potential for future healthcare paradigms.

As the demand for more effective healthcare solutions continues to rise, INOVIO's commitment to utilizing cutting-edge technology could play a vital role in overcoming the barriers faced in disease management. To find out more about INOVIO Pharmaceuticals and its pioneering efforts, visit www.inovio.com.

For media inquiries, Jennie Willson can be reached at (267) 429-8567, and for investor-related questions, Peter Vozzo from ICR Healthcare is available at (443) 213-0505.

Stay tuned as INOVIO continues to redefine healthcare through innovation, joining forces with investors keen on participating in the biomedical revolution.